Total trials
67
Active
1
Phase 3
35
Total enrollment
328,198
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| HDM SLIT-tablet | — | — | — | — | — | 3 |
Next readouts
- 2026-09-06
Top conditions
- Allergy21
- Allergic Rhinoconjunctivitis11
- Allergic Rhinitis10
- Conjunctivitis7
- Rhinitis4
- Allergic Rhinitis Due to House Dust Mite4
- Asthma4
- Rhinoconjunctivitis3
Frequently asked questions about ALK-Abelló A/S
- How many clinical trials does ALK-Abelló A/S have on ClinicalTrials.gov?
- ALK-Abelló A/S is listed as the lead sponsor on 67 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of ALK-Abelló A/S's trials are in Phase 3?
- 35 of ALK-Abelló A/S's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does ALK-Abelló A/S focus on?
- ALK-Abelló A/S's most-studied conditions on ClinicalTrials.gov are Allergy, Allergic Rhinoconjunctivitis, Allergic Rhinitis, Conjunctivitis, Rhinitis.
- When are ALK-Abelló A/S's next clinical trial readouts?
- ALK-Abelló A/S has 1 upcoming primary-completion readout tracked here; the soonest is “A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65”, expected around 2026-09-06.